Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer

C. Gridelli, G. P. Ianniello, A. Maiorino, C. Curcio, M. D'Aprile, L. Brancaccio, S. Palmeri, M. Gentile, G. Comella, T. Pedicini, G. Airoma, E. Veltri, V. Gebbia, A. Russo, R. Casaretti, F. Giampaglia, G. Ferrante, L. Rausa, S. Iacobelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent 'split-course' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.

Original languageEnglish
Pages (from-to)160-162
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number2
Publication statusPublished - 1994

Fingerprint

Epirubicin
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Drug Therapy
Therapeutics
Survival
Survivors
Radiotherapy
Thorax

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gridelli, C., Ianniello, G. P., Maiorino, A., Curcio, C., D'Aprile, M., Brancaccio, L., ... Iacobelli, S. (1994). Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 17(2), 160-162.

Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. / Gridelli, C.; Ianniello, G. P.; Maiorino, A.; Curcio, C.; D'Aprile, M.; Brancaccio, L.; Palmeri, S.; Gentile, M.; Comella, G.; Pedicini, T.; Airoma, G.; Veltri, E.; Gebbia, V.; Russo, A.; Casaretti, R.; Giampaglia, F.; Ferrante, G.; Rausa, L.; Iacobelli, S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 2, 1994, p. 160-162.

Research output: Contribution to journalArticle

Gridelli, C, Ianniello, GP, Maiorino, A, Curcio, C, D'Aprile, M, Brancaccio, L, Palmeri, S, Gentile, M, Comella, G, Pedicini, T, Airoma, G, Veltri, E, Gebbia, V, Russo, A, Casaretti, R, Giampaglia, F, Ferrante, G, Rausa, L & Iacobelli, S 1994, 'Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 17, no. 2, pp. 160-162.
Gridelli C, Ianniello GP, Maiorino A, Curcio C, D'Aprile M, Brancaccio L et al. Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials. 1994;17(2):160-162.
Gridelli, C. ; Ianniello, G. P. ; Maiorino, A. ; Curcio, C. ; D'Aprile, M. ; Brancaccio, L. ; Palmeri, S. ; Gentile, M. ; Comella, G. ; Pedicini, T. ; Airoma, G. ; Veltri, E. ; Gebbia, V. ; Russo, A. ; Casaretti, R. ; Giampaglia, F. ; Ferrante, G. ; Rausa, L. ; Iacobelli, S. / Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1994 ; Vol. 17, No. 2. pp. 160-162.
@article{5902c500c23e4ef295205bae56e0983d,
title = "Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer",
abstract = "In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent 'split-course' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5{\%} objective responses (OR) with 52.5{\%} complete responses (CR), a median survival of 14 months, with 13{\%} long-term survivors at 30 months. In extensive disease we obtained 83.6{\%} OR with 28.5{\%} CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.",
author = "C. Gridelli and Ianniello, {G. P.} and A. Maiorino and C. Curcio and M. D'Aprile and L. Brancaccio and S. Palmeri and M. Gentile and G. Comella and T. Pedicini and G. Airoma and E. Veltri and V. Gebbia and A. Russo and R. Casaretti and F. Giampaglia and G. Ferrante and L. Rausa and S. Iacobelli",
year = "1994",
language = "English",
volume = "17",
pages = "160--162",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer

AU - Gridelli, C.

AU - Ianniello, G. P.

AU - Maiorino, A.

AU - Curcio, C.

AU - D'Aprile, M.

AU - Brancaccio, L.

AU - Palmeri, S.

AU - Gentile, M.

AU - Comella, G.

AU - Pedicini, T.

AU - Airoma, G.

AU - Veltri, E.

AU - Gebbia, V.

AU - Russo, A.

AU - Casaretti, R.

AU - Giampaglia, F.

AU - Ferrante, G.

AU - Rausa, L.

AU - Iacobelli, S.

PY - 1994

Y1 - 1994

N2 - In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent 'split-course' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.

AB - In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent 'split-course' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.

UR - http://www.scopus.com/inward/record.url?scp=0028213780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028213780&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 160

EP - 162

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -